Maclean Kenneth N, Gaustadnes Mette, Oliveriusová Jana, Janosík Miroslav, Kraus Eva, Kozich Viktor, Kery Vladimír, Skovby Flemming, Rüdiger Niels, Ingerslev Jørgen, Stabler Sally P, Allen Robert H, Kraus Jan P
Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado, USA.
Hum Mutat. 2002 Jun;19(6):641-55. doi: 10.1002/humu.10089.
Cystathionine beta-synthase (CBS) is a crucial regulator of plasma levels of the thrombogenic amino acid homocysteine (Hcy). Homocystinuria due to CBS deficiency confers a dramatically increased risk of thrombosis. Early diagnosis usually occurs after the observation of ectopia lentis, mental retardation, or characteristic skeletal abnormalities. Homocystinurics with this phenotype typically carry mutations in the catalytic region of the protein that abolish CBS activity. We describe a novel class of missense mutations consisting of I435T, P422L, and S466L that are located in the non-catalytic C-terminal region of CBS that yield enzymes that are catalytically active but deficient in their response to S-adenosylmethionine (AdoMet). The P422L and S466L mutations were found in patients suffering premature thrombosis and homocystinuric levels of Hcy but lacking any of the connective tissue disorders typical of homocystinuria due to CBS deficiency. The P422L and S466L mutants demonstrated a level of CBS activity comparable to that of the AdoMet stimulated wild-type CBS but could not be further induced by the addition of AdoMet. In terms of temperature stability, oligomeric organization, and heme saturation the I435T, P422L, and S466L mutants are indistinguishable from wild-type CBS. Our findings illustrate the importance of AdoMet for the regulation of Hcy metabolism and are consistent with the possibility that the characteristic connective tissue disturbances observed in homocystinuria due to CBS deficiency may not be due to elevated Hcy.
胱硫醚β-合酶(CBS)是血栓形成性氨基酸同型半胱氨酸(Hcy)血浆水平的关键调节因子。CBS缺乏导致的同型胱氨酸尿症会显著增加血栓形成的风险。早期诊断通常在观察到晶状体异位、智力发育迟缓或特征性骨骼异常后进行。具有这种表型的同型胱氨酸尿症患者通常在该蛋白的催化区域携带突变,这些突变会消除CBS活性。我们描述了一类新的错义突变,包括I435T、P422L和S466L,它们位于CBS的非催化性C末端区域,产生的酶具有催化活性,但对S-腺苷甲硫氨酸(AdoMet)的反应不足。在患有过早血栓形成和同型胱氨酸尿症水平的Hcy但缺乏因CBS缺乏导致的同型胱氨酸尿症典型结缔组织疾病的患者中发现了P422L和S466L突变。P422L和S466L突变体表现出的CBS活性水平与AdoMet刺激的野生型CBS相当,但添加AdoMet后无法进一步诱导。就温度稳定性、寡聚体组织和血红素饱和度而言,I435T、P422L和S466L突变体与野生型CBS没有区别。我们的研究结果说明了AdoMet对Hcy代谢调节的重要性,并且与以下可能性一致:在因CBS缺乏导致的同型胱氨酸尿症中观察到的特征性结缔组织紊乱可能不是由于Hcy升高所致。